Objective: To analyze the classification, stage and prognosis of non-Hodgkin's lymphoma (NHL).
Methods: Two hundred eighty two patients with NHL were retrospectively reviewed.
Results: The complete remission (CR) rate and 5-year survival rate of B-cell NHL were higher than those of T-cell NHL(P < 0.05). There were significant differences in CR rate and 5-year survival rate among the low-grade, the intermediate-grade and the high-grade NHL(P < 0.05). The CR rate and 5-year survival rate of patients who were treated by the scheme of doxorubicin, cyclophosphamide, vincristine and prednisone (CHOP) were higher than those treated by the scheme of cyclophosphamide, vincristine, prednisone and etoposide (COP + VP16) (P < 0.05).
Conclusion: Rational classification and staging play an important role in the prognosis of NHL. CHOP-based scheme may be regarded as the first choice and the standard scheme of treatment.